Dr. Christopher C. Wright, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 590
Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
TX license P0943 (first issued 2011; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Rheumatology Associates and Subsidiary (23 clinicians)
- Arthritis Northwest PLLC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 590
- Services billed
- 120,021
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 38,560 | 12 |
| Injection, golimumab, 1 mg, for intravenous use | 22,800 | 32 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 8,475 | 11 |
| Injection, infliximab, excludes biosimilar, 10 mg | 5,940 | 19 |
| Injection, rituximab, 10 mg | 5,600 | 19 |
| Injection, denosumab, 1 mg | 3,060 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 651 | 406 |
| Blood test, comprehensive group of blood chemicals | 606 | 303 |
| Measurement c-reactive protein for detection of infection or inflammation | 602 | 300 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 596 | 298 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Dallas, TX | 460 |
| Hydroxychloroquine Sulfate Other prescribers in Dallas, TX | 389 |
| Methotrexate (methotrexate sodium) Other prescribers in Dallas, TX | 353 |
| Leflunomide Other prescribers in Dallas, TX | 210 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 191 |
| Oxycodone Hcl Other prescribers in Dallas, TX | 131 |
| Tramadol Hcl Other prescribers in Dallas, TX | 94 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Dallas, TX | 84 |
| Cyclobenzaprine Hcl Other prescribers in Dallas, TX | 82 |
| Allopurinol Other prescribers in Dallas, TX | 71 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 43 payments worth $989 in total to this clinician.
| AbbVie Inc. | $335 |
|---|---|
| Amgen Inc. | $167 |
| Lilly USA, LLC | $154 |
| AstraZeneca Pharmaceuticals LP | $143 |
| UCB, Inc. | $58.76 |
| GlaxoSmithKline, LLC. | $31.07 |
| Sobi, Inc | $24.79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.70 |
| Food and Beverage | $989 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $82,708 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2)
Novartis Pharmaceuticals Corporation - A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis
Eli Lilly and Company · Terminated · NCT05516758
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.